Src-dependent DBL family members drive resistance to vemurafenib in human melanoma

The use of selective BRAF inhibitors (BRAFi) has produced remarkable outcomes for patients with advanced cutaneous melanoma harboring a BRAF(V600E) mutation. Unfortunately, the majority of patients eventually develop drug-resistant disease. We employed a genetic screening approach to identify gain-o...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Res
Hlavní autoři: Feddersen, Charlotte R., Schillo, Jacob L., Varzavand, Afshin, Vaughn, Hayley R., Wadsworth, Lexy S., Voigt, Andrew P., Zhu, Eliot Y., Jennings, Brooke M., Mullen, Sarah A., Bobera, Jeremy, Riordan, Jesse D., Stipp, Christopher S., Dupuy, Adam J.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6774858/
https://ncbi.nlm.nih.gov/pubmed/31416844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-19-0244
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky